Insulin potentiating action of synthetic peptides relating to the amino terminal sequence of human growth hormone.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Bornstein.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Studies on ultrafiltrates of the plasma of normal and diabetic subjects have shown that a polypeptide of similar characteristics to the growth-hormone-derived polypeptide In-G is present in higher concentrations in diabetic subjects, thus indicating a possible role in the pathogenesis of diabetes mellitus. The polypeptide is absent from the plasma of hypophysectomized diabetic patients.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A pituitary polypeptide, acceleratory polypeptide-growth hormone (ACG), has been found to increase the sensitivity of fasting normal people to intravenous insulin. It is suggested that diminished activity of this polypeptide-or increased activity of another polypeptide, inhibitory polypeptide-growth hormone (ING)-may have a role in the genesis of diabetes mellitus.
A polypeptide isolated by the hydrolysis of growth hormone, studied in five patients with diabetes mellitus, has been shown able to produce hypoglycaemia, presumably by modifying the anti-insulin action of pituitary growth hormone. Possibly this substance may be suitable for treating cases of insulin resistance or when a circulating inhibitor of glucose uptake is present.
Explore the source record for details and available documents.